Phibro Animal Health Corporation (PAHC)

Currency in USD
37.67
+1.32(+3.63%)
Closed·
36.76-0.91(-2.42%)
·
PAHC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
36.3638.65
52 wk Range
28.2560.08
Key Statistics
Prev. Close
36.35
Open
36.36
Day's Range
36.36-38.65
52 wk Range
28.25-60.08
Volume
362.75K
Average Volume (3m)
267.54K
1-Year Change
1.6186%
Book Value / Share
9.5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PAHC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
44.00
Upside
+16.80%
Members' Sentiments
Bearish
Bullish
ProTips
Has maintained dividend payments for 13 consecutive years
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

1 Buy
3 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 44.00
(+16.80% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy55.00+46.00%58.00MaintainAug 28, 2026
JPMorgan
Buy58.00+53.97%58.00MaintainAug 25, 2026
Citi
Hold62.00+64.59%-New CoverageApr 15, 2026
Morgan Stanley
Hold49.00+30.08%45.00MaintainFeb 05, 2026
BofA Securities
Sell32.00-15.05%27.00MaintainNov 06, 2025

Phibro Animal Health Corporation Earnings Call Summary for Q4/2026

  • Phibro beat Q4 estimates with EPS of $0.85 vs. $0.72 expected; revenue of $396.7M topped forecasts by 3.71%, driving shares up 1.75% to $36.72.
  • Fiscal 2026 revenue hit record $1.518B, up 17% YoY; adjusted EBITDA rose 39% to $255M, boosted by Zoetis MFA acquisition and improved margins.
  • FY2027 guidance: sales of $1.55B-$1.6B, EBITDA of $258M-$268M, and EPS of $3.41-$3.59; free cash flow expected to improve as inventory normalizes.
  • Company flagged Brazil regulatory uncertainty on virginiamycin sales and near-term costs from Chicago Heights plant closure amid ongoing restructuring.
  • CEO Bendheim highlighted 'stronger operating model' from Phibro Forward program; management prioritizes organic growth, vaccine capacity expansion, and dividend support.
Last Updated: 2026-08-27, 09:58 a/m
Read Full Transcript

Earnings

Latest Release
Aug 26, 2026
EPS / Forecast
0.85 / 0.72
Revenue / Forecast
396.7M / 382.51M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.43%
Dividend Yield
1.27%
Industry Median 2.33%
Annualized payout
0.48
Paid quarterly
5-Years Growth
-
Growth Streak

PAHC Income Statement

Compare PAHC to Peers and Sector

Metrics to compare
PAHC
Peers
Sector
Relationship
P/E Ratio
15.3x−17.1x−0.4x
PEG Ratio
0.14−0.540.00
Price/Book
4.0x1.8x2.6x
Price / LTM Sales
1.0x2.4x3.1x
Upside (Analyst Target)
16.8%17.0%48.2%
Fair Value Upside
Unlock5.8%6.5%Unlock

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.

Employees
2605

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
12.08M29.74%454.88M
Other Institutional Investors
9.60M23.64%361.58M
Public Companies & Retail Investors
18.93M46.62%713.01M
Total
40.6M100.00%1.53B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.93%3,219,040121,261
FMR LLC7.78%3,159,972119,036

People Also Watch

29.60
ELMD
-1.79%
39.21
HRMY
-1.66%
22.91
OOMA
-0.56%
59.780
ETON
-4.61%

FAQ

What Is the Phibro (PAHC) Stock Price Today?

The Phibro stock price today is 37.67 USD.

What Stock Exchange Does Phibro Trade On?

Phibro is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Phibro?

The stock symbol for Phibro is "PAHC."

Does Phibro Pay Dividends? What’s The Current Dividend Yield?

The Phibro dividend yield is 1.32%.

What Is the Phibro Market Cap?

As of today, Phibro market cap is 1.48B USD.

What Is Phibro's Earnings Per Share (TTM)?

The Phibro EPS (TTM) is 2.43.

When Is the Next Phibro Earnings Date?

Phibro will release its next earnings report on Nov 11, 2026.

From a Technical Analysis Perspective, Is PAHC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Phibro Stock Split?

Phibro has split 0 times.

How Many Employees Does Phibro Have?

Phibro has 2605 employees.

What is the current trading status of Phibro (PAHC)?

As of Aug 29, 2026, Phibro (PAHC) is trading at a price of 37.67 USD, with a previous close of 36.35 USD. The stock has fluctuated within a day range of 36.36 USD to 38.65 USD, while its 52-week range spans from 28.25 USD to 60.08 USD.

What Is Phibro (PAHC) Price Target According to Analysts?

The average 12-month price target for Phibro is 44.00 USD, with a high estimate of 55 USD and a low estimate of 35 USD. 1 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +16.80% Upside potential.

What Is the PAHC Premarket Price?

PAHC's last pre-market stock price is 36.85 USD. The pre-market share volume is 20.00, and the stock has decreased by 0.50, or 1.38%.

What Is the PAHC After Hours Price?

PAHC's last after hours stock price is 36.76 USD, the stock has decreased by -0.91, or -2.42%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.